Kruger, Stephan, Ilmer, Matthias ORCID: 0000-0001-9597-1368, Kobold, Sebastian, Cadilha, Bruno L., Endres, Stefan, Ormanns, Steffen, Schuebbe, Gesa, Renz, Bernhard W., D'Haese, Jan G., Schloesser, Hans, Heinemann, Volker, Subklewe, Marion, Boeck, Stefan, Werner, Jens and von Bergwelt-Baildon, Michael (2019). Advances in cancer immunotherapy 2019-latest trends. J. Exp. Clin. Cancer Res., 38. LONDON: BMC. ISSN 1756-9966

Full text not available from this repository.

Abstract

Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively. For checkpoint blockade, current studies focus on combinational approaches, perioperative use, new tumor entities, response prediction, toxicity management and use in special patient populations. Regarding cellular immunotherapy, recent studies confirmed safety and efficacy of CAR T cells in larger cohorts of patients with acute lymphoblastic leukemia or diffuse large B cell lymphoma. Different strategies to translate the striking success of CAR T cells in B cell malignancies to other hematological and solid cancer types are currently under clinical investigation. Regarding the regional distribution of registered clinical immunotherapy trials a shift from PD-1 / PD-L1 trials (mainly performed in the US and Europe) to CAR T cell trials (majority of trials performed in the US and China) can be noted.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kruger, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ilmer, MatthiasUNSPECIFIEDorcid.org/0000-0001-9597-1368UNSPECIFIED
Kobold, SebastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cadilha, Bruno L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Endres, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ormanns, SteffenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuebbe, GesaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Renz, Bernhard W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
D'Haese, Jan G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schloesser, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heinemann, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Subklewe, MarionUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boeck, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Werner, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Bergwelt-Baildon, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-137611
DOI: 10.1186/s13046-019-1266-0
Journal or Publication Title: J. Exp. Clin. Cancer Res.
Volume: 38
Date: 2019
Publisher: BMC
Place of Publication: LONDON
ISSN: 1756-9966
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
STAGE-III MELANOMA; ADJUVANT IPILIMUMAB; AGONIST ANTIBODY; UPDATED ANALYSIS; ADVERSE EVENTS; ADULT PATIENTS; PD-1 BLOCKADE; CELL TRANSFER; FOLLOW-UP; NIVOLUMABMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/13761

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item